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Chagas disease is a zoonosis caused by Trypanosoma cruzi in which the most affected organ is the heart.
Conventional chemotherapy has a very low effectiveness; despite recent efforts, there is currently no better or more
effective treatment available. DNA vaccines provide a new alternative for both prevention and treatment of a
variety of infectious disorders, including Chagas disease. Recombinant DNA technology has allowed some vaccines
to be developed using recombinant proteins or virus-like particles capable of inducing both a humoral and cellular
specific immune response. This type of immunization has been successfully used in preclinical studies and there are
diverse models for viral, bacterial and/or parasitic diseases, allergies, tumors and other diseases. Therefore, several
research groups have been given the task of designing a DNA vaccine against experimental infection with T. cruzi.
In this review we explain what DNA vaccines are and the most recent studies that have been done to develop
them with prophylactic or therapeutic purposes against Chagas disease.
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Chagas disease is a zoonosis caused by Trypanosoma
cruzi in which the most affected organ is the heart. It is
estimated that about 10 million people are infected with
the parasite in the Americas and 25 million more are at
risk of contracting the disease [1]. The effectiveness of
conventional chemotherapy is very low; treatment is suc-
cessful in 55.8% of cases of children with early infection.
Most individuals in the chronic phase are resistant to
treatment with existing drugs and carry the infection for
their lifetime [2-4]. Despite recent efforts, there is cur-
rently no better or effective treatment available [5]. DNA
vaccines provide an alternative for both prevention and
treatment of a variety of infectious diseases, including
Chagas disease [6-8].Review
DNA vaccines
In recent years, tools of molecular biology and under-
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unless otherwise stated.helped to expand the development of vaccines. It has been
found necessary, in the case of many diseases, to produce
vaccines that induce a response by cytotoxic T lympho-
cytes (CTL). The live attenuated virus vaccines are able to
induce both CTL and humoral responses; however, the
inactivated virus and the recombinant proteins generally
do not induce a potent CTL response. The vaccines from
live attenuated organisms provide broad protection, al-
though security for certain diseases may be controversial,
such as acquired immunodeficiency syndrome because of
the potential risk of reversion to virulence through muta-
tion or recombination with a wild pathogen [9].
Recombinant DNA technology has allowed the cre-
ation of some vaccines using recombinant proteins or
virus-like particles. These vaccines are considered safe
and able to induce an efficient immune response [9,10].
A DNA vaccine can be defined as a plasmid containing a
viral, bacterial or parasitic gene that can be expressed in
mammalian cells (in the case of infectious diseases) [11,12]
or a gene encoding a mammalian protein (in the case of
non-infectious diseases such as cancer [13-15], auto-
immunity [16-18] and allergies [19-21]). The amount of
plasmid that is internalized in vivo has been estimated in
the picogram range after injection into mouse muscle [22]entral. This is an Open Access article distributed under the terms of the Creative
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days of intravenous administration of DNA complexes
with cationic lipids [23]. Because the plasmids do not rep-
licate in mammalian cells, the amount available for the
gene expression is very low. Therefore, a strong promoter/
terminator to drive the expression of the gene must be
chosen [9]. Several studies have shown that the amount of
antigen produced after inoculation of the DNA is in the
range of picograms to nanograms in vivo. Plasmid DNA is
usually inoculated into the host or animal model by direct
injection into the muscle but there are other inoculation
routes. The nucleic acid is taken up and expressed by the
host cells, causing the subsequent induction of both
humoral and cellular specific immune responses [9,10,24].
This type of immunization has been successfully used in
preclinical studies and there are diverse models for viral,
bacterial and/or parasitic diseases, allergies, tumors and
other diseases [24,25]. In recent years, the development of
vaccines against parasites has had a significant progress in
which a variety of animal models and routes of administra-
tion have been tested [26-28]; regarding Chagas disease,
several research groups have been given the task of design-
ing a DNA vaccine against experimental infection with
T. cruzi (Table 1).
DNA vaccines against Chagas disease
– Trans-sialidase family and surface proteins antigens
Garg and Tarleton immunized C57BL/6 mice with
ASP-1, ASP-2 and TSA-1 genes of the trans-sialidaseTable 1 DNA vaccines containing Trypanosoma cruzi genes fo













Vaccinia Virus BALB/c Th1
pcDNA3.1 BALB/c ND
pCMV4 BALB/c and C57BL/6 transgenic mice Th1
pcDNA3.1 Holtzman rats Th1/Th2
ND = Not determined.family and obtained few antibodies and CTL low activity.
Protection against lethal challenge was 30% to 60%. When
the interleukin-12 (IL-12) and granulocyte macrophage
colony-stimulating factor (GM-CSF) genes were co-
administered CTL activity, antibody production and re-
sistance to infection with the parasite were increased.
Lower parasitism in the tissues analyzed, less swelling
and less damage in skeletal muscle were also observed.
Survival to the challenge was 60% to 80%; greater pro-
tection by the mixture of the three genes was not gen-
erated [29].These results show that trans-sialidases,
remain good candidates for vaccines, but they are a
polymorphic gene family and response may vary accord-
ingly. Co-administration of cytokine genes enhances the
immune response.
The Boscardin group selected an amastigote surface
protein 2 (ASP-2) related-gene of T. cruzi which is an
antigen recognized by antibodies and T cells from in-
fected mice and humans. Four sets of genes were ampli-
fied using specific primers for the asp-2 gene from
amastigotes cDNA of T.cruzi Y strain and a clone with
the highest degree of identity for the gene of interest
was selected, this gene was named clone 9. BALB/c mice
immunized with a plasmid containing clone 9 gene pro-
duced specific antibodies and CD4+ T cells secreting
IFN-γ. After trypomastigote challenge a reduction in
and increased survival in the animals was observed [30].
The use of parasite surface proteins, secreted proteins or
proteins that can be expressed on the infected cell sur-
face are also of interest to identify their possible role as
important immunogens for protective induction.r prophylactic use
se Survival (%) Recombinant antigen Reference
30-60 ASP-1, ASP-2 and TSA-1 29
100 Clone 9 (ASP-2) 30
25-100 TSSA 31
ND catalytic domain of a trans-sialidase 32
ND TcG1, TcG2 and TcG4 33
92 TcSP 35
75 TcSSP4 36




25-50 ANYNFTLV epitope 43
70 Tc13 44
75 PFR2 and PFR3 45
ND CCL4/MIP-1 beta chemokine 46
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killer (NK) T cells against T. cruzi infection; they in-
fected CD1d-deficient mice with blood trypomastigotes
of Tulahuén strain and they found that the absence of
NK cells did not increase susceptibility to infection,
comparison of the parasitaemia and survival of these
animals with normal BALB/c and C57BL mice being
very similar. Subsequently, they analyzed whether ad-
ministration of α-galactosylceramide (α-GalCer) con-
ferred protection, resulting in a change in parasitaemia
only in the late stage of infection, and a slight improve-
ment in survival rate when mice were infected intraperito-
neally. The combined use of α-GalCer and benznidazole
did not increase the therapeutic efficacy of the drug, sug-
gesting that NK T cells do not play a major role in resist-
ance to infection. In order to determine whether NKcells
involved in the immunity induced by DNA immunization,
animals were immunized with the pTSSA-plasmid, which
encodes a T. cruzi trans-sialidase. It was found that para-
sitaemia was suppressed and survival in infected animals
consequently increased in those that were plasmid-
immunized, in comparison to animals immunized with the
vector alone. Co-administration of α-GalCer and pTSSA-
plasmid immunization impaired the protective effect in-
duced by theDNA, as the parasiatemia was increased and
did not improve survival compared to mice immunized
only with the empty plasmid. When mice were immunized
with DNA encoding a CD8+ T cells epitope and α-GalCer
was co-administered they showed a much lower CD8+
T cell production than those animals that were only im-
munized [31]. This study demonstrates that the induction
and activation of NK T cells can have adverse effects on
the protective immunity induced by DNA vaccination,
possibly because NK cells have Toll-like receptors capable
of recognizing parasite-infected cells and probably trans-
fected cells are deleted and thereby the activation of im-
mune response is decreased.
Mussalem et al. used Propionibacterium acnes or a
soluble polysaccharide extracted from the bacterial wall
to modulate the immune response induced by the p154/
13 plasmid containing a gene coding for the catalytic do-
main of a T. cruzi trans-sialidase. Treatment with these
adjuvants decreased the parasitaemia peak and increased
the Th1 specific immune response toward the trans-
sialidase as was observed by a low IgG1/IgG2a ratio and
in vitro strong synthesis of IFN-γ by CD4 T cells [32].
These data suggest that adjuvants can improve the DNA
vaccines protection against T. cruzi.
Bathia and Garg vaccined C57BL/6 mice with three
doses of DNA plasmid encoding TcG1, TcG2 and TcG4
antigens which are expressed in the plasma membrane
of trypomastigotes/amastigotes and also with plasmids
encoding IL-12 and GM-CSF. IgG2b/IgG1 isotypes were
associated with 50%-90% of tissue parasite load controlin the acute stage and with an undetectable parasite level
during the chronic stage. Serum and cardiac IFN-γ,
tumor necrosis factor (TNF) levels and the heart inflam-
matory infiltrate decreased in vaccinated mice during
the development of chronic disease [33]. Together, these
results demonstrated the identification of new vaccine
candidates that provide protection against T. cruzi in ex-
perimental mice.
Recently, the Carlos Slim Health Institute proposed an
important initiative to accelerate the development of a
new bivalent vaccine comprising two T. cruzi recombinant
antigens, Tc24 and TSA-1, against Chagas disease in
Mexico. A consortium including the Centro de Investiga-
ción y de Estudios Avanzados of the Instituto Politécnico
Nacional (CINVESTAV-IPN), Laboratorios de Biológicos
y Reactivos de México, S. A. de C. V. (BIRMEX) in Mexico
City, and the Centro de Investigaciones Regionales “Dr.
Hideyo Noguchi” in Mérida, state of Yucatán was formed.
This initiative will work together with a focus on develop-
ing an optimal vaccine in the least possible time [34].
The Rosales-Encina group immunized BALB/c mice with
the TcSP gene encoding a member of the trans-sialidase
family,TcSP4 gene or the recombinant proteins. The serum
cytokine analysis showed that immunization with the re-
combinant protein or with TcSP resulted in a T cell mixed
Th1-Th2 response. IFN-γ was detected in the TcSP4 gene
vaccinated-mice sera shortly after immunization, suggest-
ing a Th1 response. The immunized mice were infected
with the T. cruzi H8 strain blood trypomastigotes. Only
mice immunized with DNA showed a significant reduction
in the peak parasitaemia and lethal challenge survival
[35,36]. These studies demonstrate that DNA vaccination
induces a protective immune response in contrast to that
produced by the homologous recombinant protein during
T. cruzi experimental infection.
TcSP and TcSSP4 genes were also tested prophylactic-
ally in a canine model of Chagas disease; the antibody
analysis revealed that the dominant subclass was IgG2.
Immunization with both recombinant plasmids induced
cell mediated immunity characterized by lymph prolifer-
ation and IFN-γ production [37]. In these same animals,
immunization decreased the quality and quantity of elec-
trocardiographic changes, thereby preventing progres-
sion to more serious cardiac disorders [38]. A partial
protective effect for the prevention of macroscopic and
microscopic damage in cardiac tissue during the chronic
phase was also observed [39]. Two T. cruzi genes gener-
ating a moderate level of protection in the chronic phase
of the disease were proposed.
– Antigenic proteins
Another T. cruzi antigen that has been studied by re-
searchers is cruzipain (Cz). It has been shown that this
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parasite infection. Schanpp et al. immunized mice with
the Cz gene and showed a CTL response capable of rec-
ognizing and lysing cells infected with T. cruzi [40].
Some antigens may be immunogenic and induce protec-
tion using recombinant protein or DNA vaccination,
such as the Cz gene, which is a good candidate antigen
for the development of an anti-T. cruzi vaccine. Cz is an
enzyme that can be secreted by the parasite and it is
considered a virulence factor so if it can be blocked or
recognized on the surface of infected cells by CTL then
will be a good vaccine candidate, as was observed in this
study.
Cazorla et al. evaluated mucosal immunization in C3H/
HeN mice which received Salmonella carrying a plasmid
coding for the Cz (SCz) together with bacteria containing a
GM-CSF encoding plasmid. As an additional strategy,
prime-boost protocols were established in which mice were
vaccinated with SCz and were subsequently boosted with
recombinant Cz (rCz) co-administered with different adju-
vants, such as CpG-ODN and MALP-2 motifs. Protocols
of four SCz oral doses induced a mucosal immune re-
sponse, mainly characterized by the secretion of immuno-
globulin A (IgA) and cell proliferation of gut-associated
lymphoid tissues, with a weak systemic immune response.
In contrast, the protocol including a boost with rCZ and
CpG-ODN produced a strong systemic immune response
reflected in the titres of specific IgG against Cz, splenocyte
proliferation, interferon-gamma (IFN-γ) secretion, and
delayed hypersensitivity response. The challenge of vac-
cinated mice resulted in significantly lower levels of pa-
rasitaemia. Parasite control was also evident from the
reduction of tissue damage [41]. The results demonstrate
that administration of Salmonella-mediated Cz-DNA alone
or in combination with CpG-ODN or rCz and MALP-2
promotes the immune response to control both the infec-
tion with T. cruzi and the collateral damage to muscle
tissue.
Fralish and Tarleton performed the screening of a
cDNA expression library of T. cruzi amastigote with
monoclonal anti-amastigote antibodies and identified
the FCaBP gene encoding the flagellar Ca(2+) binding
protein, Tcβ3 gene encoding a new homologue of the
adaptin AP-3 complex β3 subunit and LYT1 gene which
encodes a secreted T. cruzi protein involved in cell lysis
and infectivity. The three gene peptides induced a re-
sponse of cytotoxic T cells in chronically infected mice;
however, the immunization with only LYT1 gene pro-
tected 80% of mice from T. cruzi lethal challenge. Alter-
natively gene mixtures were tested in immunization
assays [42]. This study demonstrates that the ability of
T. cruzi proteins to induce immune responses in in-
fected hosts, is not necessarily associated with the cap-
acity to induce protection and thus the products of theindividual genes and multigene families can serve as ef-
fective vaccines.
The Miyahira group used a recombinant adenovirus
and the vaccinia virus as vectors expressing a CD8+ T
cells epitope (ANYNFTLV), which is derived from a T.
cruzi antigen. The immunization with adenovirus and
the vaccinia virus booster was effective in inducing a cel-
lular immune response and consequently protected mice
from parasite lethal challenge. The response was increased
by co-administration of recombinant vaccinia virus ex-
pressing the receptor of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) ligand as
adjuvant [43]. The results of this group are spectacular
identifying an eight amino acid region of a molecule
able to induce a sufficient immune response to control
T. cruzi lethal infection, but again keep in mind that
the peptides to CD4T or CD8T depend on the type of
MHC for its proper recognition.
García et al. did not find antibodies when DNA plasmid
containing the gene of the Tc13 antigen of the T. cruzi
Tulahuén strain (Tc13 Tul) was administered to BALB/c
mice; however, vaccination induced specific memory T
cells with no IFN-γ production. From 40% to 80% of the
mice immunized showed signs of hepatotoxicity and heart,
liver and spleen changes five months post-immunization.
After challenge, a significant reduction in parasiatemia
during the acute stage was observed without modification
in the survival rate. The immunization resulted in de-
creased severity of cardiac damage in the chronic stage
[44]. Although in this study it is reported that the chosen
antigen induces protection in the chronic stage of the dis-
ease, hepatotoxicity, as well as heart and spleen damage
were also demonstrated. It is very important that chosen
vaccination antigens are completely safe and they induce a
significant level of protection.
Morell et al. immunized mice with DNA containing
genes forT. cruzi paraflagelar rod proteins (PFR2 and PFR3)
alone or fused to the 70 kilodalton heat shock protein
(HSP70). Both immunizations induced high levels of anti-
PFRs IgG2a; however, only the PFR2-HSP70 immunization
induced a significant increase in the IL-12 and IFN-γ ex-
pression and a decrease in the percentage of cells express-
ing IL-4 [45]. The chimerical gene immunization may
provide a protective response against T. cruzi experimental
infection.
– Non-specific T. cruzi proteins
Roffe et al. injected a cardio-toxin and four doses of
100 μg of plasmid encoding for the chemokine (C-C
motif ) ligand 4/macrophage inflammatory protein 1 beta
(CCL4/MIP-1 beta) into rats intramuscularly. After 14
days after the last immunization the rats were chal-
lenged with T. cruzi CL-Brener clone. The myocarditis
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showed a focal distribution. Increased anti-CCL4/MIP-
1beta levels in the T. cruzi infected animals were in-
duced by the immunization. This was associated with an
exacerbation of inflammation and fibrosis of the myocar-
dium, although no changes were observed in the myo-
cardial parasitism and parasitaemia rate [46]. This study
suggests that CCL4/MIP-1 beta plays a role in prevent-
ing excessive inflammation rather than the control of
parasite replication.
DNA vaccines as immunotherapy against Chagas disease
All antigens that have been used in the formulation of
therapeutic DNA vaccines belong to the trans-sialidase
family.
The Sanchez-Burgos group performed intraperitoneal
infection in ICR mice with 500 parasites. Five and 12 days
later mice were treated with 20 μg of DNA plasmid con-
taining theTSA-1, TS, ASP-2-like, Tc52 and Tc24 antigens.
The DNA treatment with the gene encoding Tc52 reduced
the parasitaemia and heart parasite load and improved the
survival, but myocarditis was not affected significantly.
The plasmids encoding Tc24 and TSA-1 significantly re-
duced parasitaemia, mortality, myocarditis and heart para-
site load [47]. These data demonstrate that the therapeutic
vaccination efficacy is dependent on the antigen and sug-
gest that DNA vaccines encoding Tc24, TSA-1 and Tc52
represent good candidates for further studies for a thera-
peutic vaccine against Chagas disease.
Dumonteil et al. infected BALB/c mice with lethal
doses of parasites and subsequently mice were treated
with two immunizations of 100 μg of DNA plasmid
containing the Tc24 antigen, starting on day 5 post-
infection. The treated animals showed parasitaemia and
heart tissue inflammation reduction; the survival was
more than 70% with TSA-1 and 100% with Tc24. Para-
sitological heart tissue analysis indicated that most of
the mice contained parasite’s kinetoplast DNA but a few
of them showed living parasites, suggesting that the im-
munotherapy was effective but did not totally eliminate
parasites [48]. In this strategy where the infection is
already established, the use of therapeutic vaccines may
help to reduce the risk of developing the acute stage of
infection and therefore the associated pathology, but the
parasite cannot be totally eliminated.
In a subsequent study, Zapata et al. investigated changes
of T cell populations induced by DNA vaccine as immuno-
therapy. The ICR mice were infected with 500 blood try-
pomastigotes and treated during the acute or chronic
stage with two doses of 100 μg of DNA. Flow cytometry
indicated that the therapeutic vaccine induced a rapid
increase in the number of CD4+ and CD8+ T cells in both
the acute and chronic stages. Also there was a rapid
increase in IFN-γ production by CD8+ T cells aftertreatment for the chronic phase. The effects of these
changes in the infection control required long periods of
time to be detectable but resulted in a myocarditis and
parasite load reduction in both stages of the infection as
tested by histopathological analysis and PCR semi-
quantitative detection of T.cruzi in cardiac tissue [49].
These results suggest that the DNA vaccines inducing
CD8+ T cell activity and IFN-γ production, as Tc24 gene,
might be good candidates for effective therapeutic vaccin-
ation against T. cruzi infection.
Aparicio-Burgos et al. induced an antigen specific IgM
and IgG response (IgG2a, IgG1) in dogs after vaccin-
ation with TcVac1, which consisted of various plasmids
encoding T. cruzi antigens, IL-12 and GM-CSF. In-
creased CD8+ T cell proliferation and IFN-γ production
as well as suppression of phagocyte activity, were ob-
served. Parasitaemia was controlled and a moderate de-
crease in the triatomine infectivity was produced by the
vaccination; however, heart parasite load and electrocar-
diographic and histopatologic alterations were not pre-
vented but were less severe than in non-immunized
dogs [50]. These results showed a moderate effect on
both the acute and the chronic stages of infection but do
not avoid the disease.
Rigato’s group used a plasmid and a human adenovirus
Type 5 (HuAd5) with a replication defect expressing the
T. cruzi amastigote surface protein 2 (ASP-2). The aim
was to elucidate the immmuno-protective memory T cell
phenotype and function. Short and long-term CD8+ T
cell populations available were compared in detail after
immunization. It was found that despite the timing, both
populations overlapped greatly with respect to functional
and phenotypic characteristics [51]. In a subsequent study
it was observed that the up-regulation of CD95 expression
and the phenotype of the pro-apoptotic pathogen-specific
CD8+ T cells expanded during infection were significantly
reduced when the adenoviral vaccine was provided at the
time of the infection. In parallel, mice vaccinated with
adenovirus and subsequently infected had a stronger cell
immune response mediated by CD8 T cells and survived
an otherwise lethal infection. It was concluded that a
suboptimal response of CD8+ T cells is associated with
up-regulation of CD95 expression and a pro-apoptotic
phenotype. Both situations can be blocked by the adeno-
viral vaccination [52].
Hoft et al. tested whether co-administration of a plas-
mid encoding IL-15 (pIL-15) and a plasmid encoding
trans-sialidase (pTS) of Trypanosoma cruzi could im-
prove the duration of protection, this co-administration
did not significantly alter the T cell response or the pro-
tection shortly after immunization. However, mice vacci-
nated with both plasmids and challenged 6 months post
immunization were significantly more protected than
those who received only the gene of T. cruzi. Improved
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cific IFNγ-producing T cells against trans-sialidase [53].
It was shown here that IL-15 may have a significant ef-
fect as an adjuvant for induction of increased protection
against T. cruzi.
Nogueira et al. used the yellow fever virus as a vector
to immunize mice with the gene encoding the T. cruzi
ASP-2. It was shown that the recombinant virus YF17D/
ENS1/Tc was capable of priming CD8+ T cells directed
against the T. cruzi TEWETG1 epitope producing IFN-γ
after challenge [54]. This study shows that the use of
viral formulations can be a good strategy to induce pro-
tective immune responses against pathogens.
Conclusions
DNA vaccines have provent o be effective in a variety of
preclinical models. This technology has been adopted by
many researchers as a strategy to develop a suitable
vaccine against Chagas disease. It has explored various im-
munogens (genes encoding a variety of T. cruzi proteins),
and routes of administration as well as the use of
immunomodulators.
Although no vaccine has been able to prevent the in-
fection, in some cases immunizations have induced par-
tial protection; these studies provide data that proves the
feasibility of preventive and therapeutic DNA vaccines to
control the T. cruzi infection. However, a better under-
standing of the protective immune responses that can ef-
fectively stop parasite development and contribute to
the understanding and development of an effective vac-
cine remains necessary.
Prophylactic vaccines in humans would be a very ef-
fective control method for Chagas disease, which would
also be further improved if they were also used in the
veterinary sectors.
The therapeutic use of DNA vaccines against Chagas
disease could improve the effectiveness of current treat-
ment and thus provide a better prognosis for the patient.
These vaccines for therapeutic use have shown no ad-
verse or toxic effects.
The prophylactic or therapeutic DNA vaccines have
been shown to reduce the duration and signs of the
acute stage, whereas in the chronic phase have avoided
or lessened the severity of heart damage and thereby
prolonged the patients’ lifetime.
Prophylactic vaccines have failed so far to prevent
parasitic infection; therefore, the current challenge is to
identify the ideal antigen.
There is a need to create new formulations that can
improve the existing protection achieved so far, as well
as to test new methods of administration.
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